Screening for rare genetic variants associated with atherosclerosis: opportunity for personalized medicine.
Abstract Atherosclerosis and its clinical manifestations is a leading cause of disease burden worldwide. Currently, most of the individuals carrying a strong predisposition to complications of atherosclerosis because of monogenic dyslipidaemias remain undiagnosed and consequently are not given an opportunity for prevention. Therefore, one of the main public health challenges remains the identification of individuals with significantly increased risk for atherosclerosis due to monogenic predisposition. Next-generation sequencing (NGS) has revolutionized genetic testing in symptomatic patients. Although new genomic ...
Source: Current Vascular Pharmacology - February 5, 2018 Category: Drugs & Pharmacology Authors: Peterlin A, Petrovic D, Peterlin B Tags: Curr Vasc Pharmacol Source Type: research

Caveolin-1 in stroke neuropathology and neuroprotection: a novel molecular therapeutic target for ischemic-related injury.
Abstract Cardiovascular disease and associated cerebral stroke are a global epidemic attributed to genetic and epigenetic factors, such as diet, life style and an increasingly sedentary existence due to technological advances in both the developing and developed world. There are approximately 5.9 million stroke-related deaths worldwide annually. Current epidemiological data indicate that nearly 16.9 million people worldwide suffer a new or recurrent stroke yearly. In 2014 alone, 2.4% of adults in the United States (U.S.) were estimated to experience stroke, which is the leading cause of adult disability and the fi...
Source: Current Vascular Pharmacology - February 5, 2018 Category: Drugs & Pharmacology Authors: Wang S, Head BP Tags: Curr Vasc Pharmacol Source Type: research

Genetic variations and subclinical markers of carotid atherosclerosis in patients with type 2 diabetes mellitus.
Abstract Atherosclerosis and its cardiovascular complications are the main cause of death in diabetic patients. Patients with diabetes mellitus have a greater than 10-fold risk of cardiovascular disease in their lifetime. The carotid intima-media thickness (cIMT), a surrogate marker for the presence and progression of atherosclerosis, predicts future cardiovascular events in asymptomatic subjects with type 2 diabetes mellitus (T2DM). This review focuses on genetic variants that contribute to the pathobiology of subclinical atherosclerosis in the setting of T2DM. Specifically, we devoted our attention to well-studi...
Source: Current Vascular Pharmacology - February 5, 2018 Category: Drugs & Pharmacology Authors: Ramus SM, Petrovic D Tags: Curr Vasc Pharmacol Source Type: research

Prevention of vascular complications in diabetes mellitus patients: focus on the arterial wall.
Abstract In diabetes mellitus (DM), hyperglycaemia and insulin resistance progressively lead to both microvascular and macrovascular complications. Whereas the incidence of microvascular complications is closely related to tight glycaemic control, this does not apply to macrovascular complications. Hyperglycaemia influences many interweaving molecular pathways that initially lead to increased oxidative stress, increased inflammation and endothelial dysfunction. The latter represents the initial in both types of vascular complications; it represents the "obligatory damage" in microvascular complications d...
Source: Current Vascular Pharmacology - February 5, 2018 Category: Drugs & Pharmacology Authors: Lunder M, Janic M, Sabovic M Tags: Curr Vasc Pharmacol Source Type: research

Does Perioperative Hemoglobin A1c Level Affect the Incidence, Pattern and Mortality of Lower Extremity Amputation?
Abstract We hypothesized that perioperative HbA1c influenced the pattern and outcomes of lower extremity amputation (LEA). A retrospective analysis was conducted for all patients who underwent LEA between 2000 and 2013. Patients were categorized into 5 groups according to their perioperative HbA1c values [Group 1 (
Source: Current Vascular Pharmacology - January 22, 2018 Category: Drugs & Pharmacology Authors: Al-Thani H, El-Matbouly M, Al-Sulaiti M, Al-Thani N, Asim M, El-Menyar A Tags: Curr Vasc Pharmacol Source Type: research

Is there Sex-related Outcome Difference according to oral P2Y12 inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients.
Conclusion In summary, in comparison to monotherapy with aspirin, P2Y12 inhibitors reduce MACE in women and men. Ticagrelor was shown to be superior to clopidogrel in both sexes. Prasugrel showed a statistically significant benefit only in men; however indirect comparison did not demonstrate superiority of ticagrelor over prasugrel in women. PMID: 29359672 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 22, 2018 Category: Drugs & Pharmacology Authors: Brown OI, Rossington JA, Buchanan GL, Patti G, Hoye A Tags: Curr Vasc Pharmacol Source Type: research

Non-traditional Cardiovascular Risk Markers in the Era of Established Major Risk Factors and Multiple Guidelines.
Abstract The non-traditional cardiovascular (CV) risk factors that appear to be of most clinical interest include: apolipoprotein A (ApoA), apolipoprotein B (ApoB), high-sensitivity C-Reactive protein (hsCRP), homocysteine, interleukin 1 (IL1), lipoprotein (a) [Lp(a)], the density of low-density lipoprotein (LDL) particles, the LDL particle number, tissue/tumor necrosis factor-α (TNF-α) and uric acid. These non-traditional risk factors may be of value in adding further confirmation and attention to suspected significant CV risk. They can also provide a better understanding of current concepts of athero...
Source: Current Vascular Pharmacology - January 22, 2018 Category: Drugs & Pharmacology Authors: Whayne TF Tags: Curr Vasc Pharmacol Source Type: research

Patient adherence to Novel Oral Anticoagulants (NOACs) for the treatment of Atrial Fibrillation and occurrence of associated bleeding events: A Systematic Review and Meta-analysis.
CONCLUSION: Suboptimal adherence to NOACs among AF patients was highlighted as a significant risk factor that may affect clinical outcomes, with a higher percentage of non-adherent patients having bleeding events. There is an urgent need for research on the effects of specific interventions to improve patient adherence to NOACs and to assess the related outcome factors that may be associated with adherence. PMID: 29359674 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 22, 2018 Category: Drugs & Pharmacology Authors: Shehab A, Bhagavathula AS, Abebe TB, Abegaz TM, Elnour AA, Sabbour HM, Uzzafer M, Hersi A, Hamad AK Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Controversies in the cath lab: navigating contemporary conundrums before, during and after intervention.
PMID: 29345583 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 17, 2018 Category: Drugs & Pharmacology Authors: Gorog D, Geisler T Tags: Curr Vasc Pharmacol Source Type: research

Antithrombotic therapy after TAVR.
Abstract Transvascular aortic valve replacement (TAVR) has emerged as a treatment option in patients with severe aortic stenosis who are inoperable and has recently been evaluated in patients with intermediate surgical risk. The number of procedures is increasing worldwide in parallel with the demographic changes in industrial countries. The risk for cerebral embolism is of main concern and represents a major determinant for prognosis and quality of live after TAVR. The empiric antithrombotic therapy consists of dual antiplatelet therapy (DAPT); however the risk-benefit of this approach is lacking evidence from ra...
Source: Current Vascular Pharmacology - January 17, 2018 Category: Drugs & Pharmacology Authors: Geisler T, Droppa M, Mueller K, Borst O Tags: Curr Vasc Pharmacol Source Type: research

Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox.
CONCLUSION: Whilst clearly definitive, adequately powered, randomised controlled trials are lacking, we would recommend avoiding the combination of morphine with oral P2Y12 receptor inhibitors and recommend alternative strategies including intravenous platelet inhibitor strategies, in high risk patients. PMID: 29345594 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 17, 2018 Category: Drugs & Pharmacology Authors: Farag M, Spinthakis N, Srinivasan M, Gorog DA Tags: Curr Vasc Pharmacol Source Type: research

Mechanical support in cardiogenic shock complicating acute coronary syndrome: ready for prime time?
Abstract Cardiogenic shock (CS) is a major challenge in current cardiology. Over the last decade, cardiogenic shock mortality has decreased somewhat, but it still remains high, particularly when associated with ischaemic heart disease. The challenges are numerous and include prevention, accurate diagnosis, prompt management and effective therapies to support a failing heart and prevent multi-organ failure. Despite improvements in the care of acute coronary syndrome (ACS), it remains the most common cause of CS. In addition to existing medical therapy, mechanical circulatory support has been proposed for the manage...
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Schurtz G, Laine M, Delmas C, Kerbaul F, Puymirat E, Lemesle G, Bonello L Tags: Curr Vasc Pharmacol Source Type: research

Mandatory reporting of coronary artery calcifications incidentally noted on chest multi-detector computed tomography: a multicentre experience.
CONCLUSIONS Radiologists can note the distribution of CACs on a chest MDCT and should mandatorily record them in their reports. Depending on CAC presence and location, these findings may have important clinical implications, mostly in asymptomatic patients with intermediate FRS. This information may reclassify a patients' CV risk and improve clinical management. PMID: 29345585 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Cappabianca S, Belfiore MP, Reginelli A, Capasso R, Del Prete A, Petrillo M, Mascia P, Rossi C, Romano F, De Filippo M, Scialpi M, Gragnano F, Calabro P, Belfiore G, Brunese L, Grassi R, Rotondo A Tags: Curr Vasc Pharmacol Source Type: research

What is the role of Cangrelor in patients undergoing PCI?
Abstract Dual antiplatelet therapy with aspirin and oral P2Y12-receptor inhibitors prevents ischemic events in patients undergoing percutaneous coronary intervention (PCI). However oral administration of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naïve patients. Cangrelor is a novel P2Y12-receptor inhibitor which is administrated intravenously and thus allows immediate antiplatelet inhibition during PCI. Due to its unique pharmacokinetics with fast onset of platelet inhibition and very short plasma half-life it allows effective and controllable periprocedural platelet in...
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Droppa M, Geisler T Tags: Curr Vasc Pharmacol Source Type: research

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation?
CONCLUSION: More potent antithrombotic regimens increase bleeding and should only be considered on an individual basis, after careful risk stratification. Accurate risk stratification of ACS patients, for both ischaemic and bleeding risk, is essential to allow individualised treatment. PMID: 29345587 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Spinthakis N, Farag M, Akhtar Z, Gorog DA Tags: Curr Vasc Pharmacol Source Type: research

The Role of Percutaneous Coronary Intervention in the Treatment of Chronic Total Occlusions: Rationale and Review of the Literature.
CONCLUSIONS: CTO-PCI is a rapidly expanding specialized procedure in interventional cardiology and is reasonable or indicated if the occluded vessel is responsible for symptoms or in selected patients with silent ischemia in whom there is a large amount of myocardium at risk and PCI is likely to be successful. PMID: 29345588 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Agrawal H, Lange R, Montanez R, Wali S, Mohammad KO, Kar S, Teleb M, Mukherjee D Tags: Curr Vasc Pharmacol Source Type: research

Neonatal systemic thrombosis: an updated overview.
Abstract Thromboembolic disease is a complex disorder with a multifactorial aetiology and a severe outcome. In newborns and children it may be missed or diagnosed late, thus worsening the prognosis. The neonatal disease is different from the disorder affecting older children and adults. However, scant epidemiological data and few randomised clinical trials regarding paediatric patients are available, and treatment recommendations are largely based on adult guidelines. Younger patients then have several decades over which they will suffer from the complications of thrombosis and risk of a new thrombotic episode. Cu...
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Signorelli SS, Conti GO, Molinari AC, Ruggieri M, Grasso A, Ferrantea M Tags: Curr Vasc Pharmacol Source Type: research

What is the role for Glycoprotein IIb/IIIa inhibitor use in the catheterisation laboratory in the current era?
CONCLUSION: Because of the persistent benefit of GPI in limiting early ischemic complications, especially in higher risk clinical and/or anatomical subsets, and the associated risk of increased bleeding complications, also in contemporary PCI, these agents should currently be used on a selective rather than routine basis, including bail out administration for peri-procedural thrombotic complications. PMID: 29345590 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Rubboli A, Patti G Tags: Curr Vasc Pharmacol Source Type: research

Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians? Focused on ACS or PCI-treated Patients.
Abstract With over 1.5 billion people, East Asians are the most populous race in the world. Health status in this population is an important global issue. In the contemporary trials of antithrombotic treatment, East Asian patients have a lower risk for atherothrombotic diseases (especially, coronary artery disease [CAD]) and a higher risk for bleeding (especially, gastrointestinal bleeding and hemorrhagic stroke). Despite these observations, antithrombotic treatment strategies in East Asian patients are mainly based on the American or European guidelines that are derived from randomized, controlled trials includin...
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Bae JS, Ahn JH, Tantry U, Gurbel PA, Jeong YH Tags: Curr Vasc Pharmacol Source Type: research

Prolonging ticagrelor beyond a year of acute coronary syndrome: worth or harmful?
Abstract Platelet activation plays a central role in triggering and complicating acute coronary syndromes, especially in case of stent thrombosis and myocardial infarction. On top of aspirin, P2Y12-inhibitors are successfully used to treat and prevent these events for a duration of one year after an acute coronary episode or 6 months after drug-eluting stent implantation. However, patients with acute coronary syndromes remain at heightened risk for recurrent ischemic events after the recommended durations of P2Y12-inhibitors and therefore, prolonging treatment is often considered in clinical practice. However, the...
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Aradi D, Dezsi D, Veress G, Merkely B Tags: Curr Vasc Pharmacol Source Type: research

Editorial: News in Cardiovascular Surgery Treatment: Is there Anything to do Before and After it?
PMID: 29308740 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 7, 2018 Category: Drugs & Pharmacology Authors: Orriach JLG, Aliaga MR Tags: Curr Vasc Pharmacol Source Type: research

Associations between adiponectin gene variability, pro-inflammatory and angiogenetic markers: implications for microvascular disease development in type 2 diabetes mellitus?
CONCLUSION: Genetic variability on adiponectin gene was associated with serum levels of inflammatory and angiogenetic markers. Further research is required to elucidate the role of adiponectin in the development and/or progression of microvascular disease in T2DM patients. PMID: 29308741 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 7, 2018 Category: Drugs & Pharmacology Authors: Kollia C, Antonopoulos AS, Siasos G, Konsola T, Oikonomou E, Gouliopoulos N, Tsigkou V, Papapanagiotou A, Kassi E, Tentolouris N, Katsiki N, Vavuranakis M, Papavassiliou AG, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Atherogenic index of plasma is associated with body fat level in type 2 diabetes mellitus patients.
Abstract OBJECTIVE: To investigate the characteristics of body fat distribution and the relationship between body fat index and atherogenic index of plasma (AIP) in type 2 diabetes mellitus (T2DM) patients. METHODS: A total of 316 participants were divided into a T2DM group and a non-diabetes group (controls). According to the visceral fat area (VFA), all participants were further divided into VFA ≥100 cm2 and VFA
Source: Current Vascular Pharmacology - January 3, 2018 Category: Drugs & Pharmacology Authors: Song P, Xu L, Xu J, Zhang HQ, Yu CX, Guan QB, Zhao M, Zhang X Tags: Curr Vasc Pharmacol Source Type: research

Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature.
CONCLUSION: Selective thromboaspiration for angiographically visible thrombi in MI patients undergoing PCI, as an adjunct to mechanical reperfusion and to IIb/IIIa-inhibitors, may be an option since this manoeuvre may improve procedural and clinical outcome. PMID: 29298651 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 1, 2018 Category: Drugs & Pharmacology Authors: Manolis AS Tags: Curr Vasc Pharmacol Source Type: research

Aortic stenosis, aortic regurgitation and arterial hypertension.
CONCLUSION: Several lines of evidence support a detrimental association between HT and aortic valve disease. Therefore, HT should be promptly treated in aortic valvulopathy. Despite conventional wisdom, specific vasodilators can be used with caution in aortic stenosis. PMID: 29295699 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 1, 2018 Category: Drugs & Pharmacology Authors: Katsi V, Georgiopoulos G, Oikonomou D, Aggeli C, Grassos C, Papadopoulos DP, Thomopoulos C, Marketou M, Dimitriadis K, Toutouzas K, Nihoyannopoulos P, Tsioufis C, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Serum uric acid is independently associated with diastolic dysfunction in apparently healthy subjects with essential hypertension.
CONCLUSIONS: In hypertensive subjects without HF, UA is independently associated with the presence of DD in both genders and correlates with its severity in women. Further prospective studies are warranted to evaluate the association of UA with adverse cardiovascular outcomes in high-risk populations such as HF with pEF. PMID: 29278214 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 26, 2017 Category: Drugs & Pharmacology Authors: Georgiopoulos G, Tsioufis CP, Kalos T, Magkas N, Rousos D, Chrysohoou C, Sarri G, Syrmali K, Georgakopoulos P, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Preface.
PMID: 29258414 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 22, 2017 Category: Drugs & Pharmacology Authors: Mikhailidis DP Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Uncontrolled Hypertension and Related Comorbidities: A Clinician's Update.
PMID: 29258415 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 22, 2017 Category: Drugs & Pharmacology Authors: Tsioufis C, Mahfoud F, Mancia G, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
PMID: 29210655 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 4, 2017 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Doumas M Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Arterial Stiffness, Central Haemodynamics and Non-Alcoholic Fatty Liver Disease: Links with Cardiovascular Risk and Effects of Drug Treatment.
Abstract Arterial stiffness, central haemodynamics and non-alcoholic fatty liver disease (NAFLD) have been associated with increased risk for cardiovascular (CV) morbidity and mortality. Antihypertensive, antidiabetic and hypolipidaemic drugs may affect these predictors of CV risk. Such associations should be taken into consideration when treating high-risk patients. PMID: 29210656 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 4, 2017 Category: Drugs & Pharmacology Authors: Katsiki N, Imprialos K, Vlachopoulos C Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis.
PMID: 29210657 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 4, 2017 Category: Drugs & Pharmacology Authors: Paschou SA, Anagnostis P, Vryonidou A, Goulis DG Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Matrix Metalloproteinases as Markers of Atherosclerosis in Renal Patients: Are we there Yet?
PMID: 29210658 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 4, 2017 Category: Drugs & Pharmacology Authors: Panayiotou AG, Kouis P, Kousios A Tags: Curr Vasc Pharmacol Source Type: research

Editorial: β-Adrenergic Receptor Gene Polymorphisms and its Relationship with Heart Failure.
Editorial: β-Adrenergic Receptor Gene Polymorphisms and its Relationship with Heart Failure. Curr Vasc Pharmacol. 2017 Dec 04;: Authors: Kolovou G, Kolovou V, Mavrogeni S PMID: 29210659 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 4, 2017 Category: Drugs & Pharmacology Authors: Kolovou G, Kolovou V, Mavrogeni S Tags: Curr Vasc Pharmacol Source Type: research

Paraoxonase-1: Characteristics and role in atherosclerosis and carotid artery disease.
Abstract Paraoxonase-1 (PON-1) is a calcium-dependent enzyme that is synthesized in the liver and then secreted in blood where it is bound to high density lipoprotein(HDL). PON-1 is a hydrolase with a wide range of substrates, including lipid peroxides. It is considered responsible for many of the antiatherogenic properties of HDL. PON-1 prevents low density lipoprotein (LDL) oxidation, a process that is considered to contribute to the initiation and development of atherosclerosis. PON-1 activity and levels areinfluenced by gene polymorphisms; of the 2 common variants, one is in position 192 (Q192R) and one in pos...
Source: Current Vascular Pharmacology - November 29, 2017 Category: Drugs & Pharmacology Authors: Lioudaki S, Verikokos C, Kouraklis G, Ioannou C, Chatziioannou E, Perrea D, Klonaris C Tags: Curr Vasc Pharmacol Source Type: research

Calcium-Channel Sensitizers in Cardiac Surgery: Who, When, How and Why.
Abstract we try to answer four questions in this review, what type of patients need this drug; what is the best time to start with it, the best way that we could give it and finally the reasons for use it. PMID: 29149814 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - November 16, 2017 Category: Drugs & Pharmacology Authors: Orriach JLG, Fernandez AR, Belmonte JJE, Navarro MR, Navarro MR, Manas JC Tags: Curr Vasc Pharmacol Source Type: research

Stroke and Hypertension: an Appraisal from Pathophysiology to Clinical Practice.
Abstract Stroke as a cause of long-term disability is a growing public health burden. Therefore, focusing on prevention is important. The most prominent aim of this strategy is to treat modifiable risk factors, such as arterial hypertension, the leading modifiable contributor to stroke. Thus, efforts to adequately reduce blood pressure (BP) among hypertensives are mandatory. In this respect, although safety and benefits of BP control related to long-term outcome have been largely demonstrated, there are open questions that remain to be addressed, such as optimal timing to initiate BP reduction and BP goals to be t...
Source: Current Vascular Pharmacology - November 16, 2017 Category: Drugs & Pharmacology Authors: Buonacera A, Stancanelli B, Malatino L Tags: Curr Vasc Pharmacol Source Type: research

Maternal Dyslipidaemia in Pregnancy with Gestational Diabetes Mellitus: Possible Impact in the Foetoplacental Vascular Function and the Lipoprotein in the Neonatal Circulation.
Abstract Dyslipidaemia occurs in pregnancy to secure foetal development. The mother shows a physiological increase in plasma total cholesterol and triglycerides (TG) as pregnancy progresses (i.e. maternal physiological dyslipidaemia in pregnancy). However, in some women pregnancy-associated dyslipidaemia exceeds this physiological adaptation. The consequences of this condition on the developing foetus include endothelial dysfunction of the foetoplacental vasculature and development of foetal aortic atherosclerosis. Gestational diabetes mellitus (GDM) associates with abnormal function of the foetoplacental vasculat...
Source: Current Vascular Pharmacology - November 16, 2017 Category: Drugs & Pharmacology Authors: Contreras-Duarte S, Carvajal L, Fuenzalida B, Cantin C, Sobrevia L, Leiva A Tags: Curr Vasc Pharmacol Source Type: research

High-density lipoprotein (HDL) Dysfunction and Future of HDL.
Abstract Although high density lipoprotein cholesterol (HDL-C) levels are inversely proportional to cardiovascular risk in many studies, recent pharmacological interventional studies with HDL-C raising strategies did not show a benefit in terms of vascular events. The HDL particle is heterogenous with anti-atherogenic functions and non-vascular effects. Many factors affect HDL components and may either cause compositional changes, post-translational modifications of proteins, or alter lipids and other cargo molecules; generally these factors cause more than one of these changes, resulting in functional differences...
Source: Current Vascular Pharmacology - November 16, 2017 Category: Drugs & Pharmacology Authors: Ertek S Tags: Curr Vasc Pharmacol Source Type: research

Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair.
Abstract Abdominal aortic aneurysm (AAA) is a degenerative disease of the aortic wall with potentially fatal complications. Open repair (OR) was considered the gold standard, until the emergence of endovascular aneurysm repair (EVAR), which is less invasive and equally (if not more) effective. As the popularity of endovascular procedures grows, related complications become more evident, with kidney damage being one of them. Although acute kidney injury (AKI) following EVAR is relatively common, its true incidence is still uncertain. Also, there is insufficient data concerning long-term renal outcomes after EVAR, e...
Source: Current Vascular Pharmacology - November 16, 2017 Category: Drugs & Pharmacology Authors: Isenovic E, Radak D, Neskovic M, Otasevic P Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Risk in Psoriasis: Current State of the Art.
Abstract Psoriasis (Pso) is a chronic inflammatory immune-mediated skin disease associated with several comorbidities. Despite the growing number of studies providing evidence for the link between Pso and cardiovascular (CV) disorders, there are still many unsolved questions, dealing with the role of the skin disease as an independent risk factor for CV events, the influence of Pso severity and duration on CV damage, the presence of psoriatic arthritis (PsA) as a predictor of increased CV mortality and morbidity and the detection of reliable clinical, laboratory and/or instrumental parameters to stratify CV risk i...
Source: Current Vascular Pharmacology - November 16, 2017 Category: Drugs & Pharmacology Authors: Dattilo G Tags: Curr Vasc Pharmacol Source Type: research

Mechanisms of Cardioprotection of Halogenated Agents during Extracorporeal Circulation in Cardiac Surgery.
Abstract The implementation of cardioprotective strategies involving pre-, intra-, and postoperative interventions is key during cardiac surgery requiring extracorporeal circulation (ECC). The primary goal of this study was to review the physiopathology of and protection strategies against myocardial damage secondary to ECC during cardiac surgery. The administration of halogenated anesthetics for cardiac anesthesia is commonplace due to their well-known cardioprotective effects and their capacity to ensure hypnosis. An optimal myocardial protection strategy requires that a comprehensive approach is adopted to cove...
Source: Current Vascular Pharmacology - November 16, 2017 Category: Drugs & Pharmacology Authors: Aliaga MR, Belmonte JJE, Ramirez-Fernandez A, Navarro MR, Manas JC Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Vascular Protection of Herbal Medicine: Roles and Mechanisms.
PMID: 29022508 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 13, 2017 Category: Drugs & Pharmacology Authors: Liu Y, Liu Y Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Relationship between Vitamin D and Metalloproteinases (MMPs) in Acute Myocardial Infarction (AMI).
PMID: 28982337 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 4, 2017 Category: Drugs & Pharmacology Authors: Perovic M, Obradovic M, Resanovic I, Isenovic ER Tags: Curr Vasc Pharmacol Source Type: research

Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod-induced Psoriatic Mouse Model.
Abstract Background Psoriasis is a chronic inflammatory skin disorder of unknown etiology. Increasing evidence suggests that psoriasis is probably an angiogenesis-dependent disease. Thalidomide has been reported being able to inhibit the effects of fibroblast growth factor 2 and vascular endothelial growth factor (VEGF), and inhibit tumour necrosis factor-alpha synthesis, and suppress tumour necrosis factor-induced nuclear factor-kappa B activation in Jurkat cells, resulting in suppression of proliferation inflammation, angiogenesis, and the immune system, which are related to the pathogenesis of psoriasis. Object...
Source: Current Vascular Pharmacology - October 4, 2017 Category: Drugs & Pharmacology Authors: Liu JH, Wu HH, Zhao YK, Wang F, Gao Q, Luo DQ Tags: Curr Vasc Pharmacol Source Type: research

The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review.
CONCLUSION: Based on the reviewed literature, allopurinol appears to be a promising therapy to improve vascular function and reduce disability in patients who have had a stroke. The benefits seen are in combination with current standard of care treatments with aspirin and lipid-lowering therapy. Larger trials are necessary to better understand the role of allopurinol in patients with history of stroke. PMID: 28933307 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - September 19, 2017 Category: Drugs & Pharmacology Authors: Britnell SR, Chillari KA, Brown JN Tags: Curr Vasc Pharmacol Source Type: research

Polymorphism Gln27Glu of β2 adrenergic receptors in patients with ischaemic cardiomyopathy.
CONCLUSION: The present study shows that the Gln27Gln genotype of β2-AR is the most predominant while the Glu27Glu is the least prevalent in our HF population. There was no difference in the prevalence of polymorphism Gln27Glu between HF patients and control subjects. However, the presence of Glu allele was associated with lower myocardial infarction rate. PMID: 28933308 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - September 19, 2017 Category: Drugs & Pharmacology Authors: Metaxa S, Missouris C, Mavrogianni D, Miliou A, Oikonomou E, Vlismas A, Toli E, Kormali L, Drakakis P, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Cigarette smoking is associated with decreased Bone Gla-protein (BGP) levels in hemodialysis patients.
CONCLUSION: This is the first clinical study in a haemodialysis population, which identifies cigarette smoking as a potential factor that can lower BGP levels, a protective agent in bone and vascular health. PMID: 28933309 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - September 19, 2017 Category: Drugs & Pharmacology Authors: Fusaro M, Gallieni M, Aghi A, Iervasi G, Rizzo MA, Stucchi A, Noale M, Tripepi G, Nickolas T, Veronese N, Fabris F, Giannini S, Calò L, Piccoli A, Mereu MC, Cosmai L, Ferraro A, Magonara F, Spinello M, Sella S, Plebani M Tags: Curr Vasc Pharmacol Source Type: research

Pulmonary Hypertension secondary to Left Heart Disease.
Abstract BACKGROUND: Pulmonary hypertension (PH) related to left heart disease (LHD) is the most common form of PH, accounting for more than two third of all PH cases. The hemodynamic abnormalities seen in PH-LHD are complex, and there are currently minimal evidence-based recommendations for the management of PH-LHD. While it is accepted that PH in the context of left heart disease is a marker of worse prognosis, it remains unclear whether its primary treatment is beneficial or harmful. In this article, we discuss the prevalence and significance of PH in patients with heart failure (HF) with reduced ejection fract...
Source: Current Vascular Pharmacology - September 12, 2017 Category: Drugs & Pharmacology Authors: Kabbach G, Mukherjee D Tags: Curr Vasc Pharmacol Source Type: research

Animal Models of Focal Cerebral Ischaemia and Haemorrhagic Transformation: Considerations in Experimental Stroke Study Design.
Abstract Ischaemic stroke is often complicated with haemorrhage within the infarct zone or in a remote location especially when treated with intravenous thrombolysis and/or thrombectomy. While these early recanalisation treatments are highly effective, some of the benefit is lost because of haemorrhagic complications and consequential neurological deterioration of the patients. A number of mechanisms have been described that mediate the haemorrhagic changes and several agents have been tested in experimental models for inhibiting post stroke haemorrhage. Here, we review and discuss the small animal models of focal...
Source: Current Vascular Pharmacology - September 5, 2017 Category: Drugs & Pharmacology Authors: Shearer JA, Douglas AS, Kirby BP, Tatlisumak T, Doyle KM Tags: Curr Vasc Pharmacol Source Type: research

Is There An Association Between Periodontitis And Atherosclerosis In Adults? A Systematic Review.
CONCLUSION: The available evidence indicates an association between the 2 diseases, with elevated levels of inflammatory markers, mainly C-reactive protein and interleukin 6. PMID: 28875830 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 30, 2017 Category: Drugs & Pharmacology Authors: Almeida APCPSC, Fagundes NCF, Maia LC, Lima RR Tags: Curr Vasc Pharmacol Source Type: research